snowdeal.org > {bio,medical}informatics

{bio,medical} informatics

Tuesday, November 20, 2001

bookmark: connotea :: del.icio.us ::digg ::furl ::reddit ::yahoo::

The New York Times Exelixis in Deal for Genomica
[requires 'free' registration]

"Exelixis said yesterday that it would acquire Genomica, a maker of software for genetic analysis, for about $110 million in stock in a sign of further consolidation in the genomics business.

The price is roughly equivalent to the amount of cash and long-term investments held by Genomica, indicating that Exelixis is picking up Genomica's software essentially for nothing.

GenomeWeb Exelixis to Acquire Genomica for its Cash
"Exelixis CEO George Scangos said although his company intends to use Genomica's software for its internal drug development activities, he stressed that he does not plan to continue commercial sales of the firm's products and said that he is more interested in Genomica's assets, which as of Sept. 30 comprised $110.8 million in cash, cash equivalents, and investments.

"We do not intend to get into the software business," said Scangos in a conference call to discuss the acquisition. "We believe that Genomica's substantial cash and investments will significantly enhance our ability to move our drug-discovery programs forward, and that their software will be an important tool to manage human data during the clinical development of our compounds.""

Fool.Com Bioinformatics Takeover Candidates
"A new Frost & Sullivan report augurs an explosion in the U.S. bioinformatics market from $1.38 billion in 2000 to $6.9 billion in 2007. The industry is full of players, and there's almost certain to be consolidation. The friendly capital markets of 1999 and 2000 allowed many to raise enough cash to hold out for the best bid."

redux [10.17.01]
CIO Magazine Drug Companies On Speed
""We're an information-based industry, but we've been a bit behind in the extent to which we've been using computer-based tools," Dinerstein says. "They've had better computer models for oil drilling than we've had for drug discovery."

While executives in this closely guarded industry won't say how much they're investing in research and development informatics, they are definitely hopping on board. Merck & Co. in Whitehouse Station, N.J., recently paid $620 million to acquire Rosetta Inpharmatics, a genomics and technology company based in Kirkland, Wash. And New York City-based Pfizer says it recently spent more than $100 million to create an "integrated system of high-speed discovery technologies." Pradip Banderjee, a senior partner with Accenture Consulting, conservatively estimates that drugmakers as a whole spend more than $4 billion a year on that kind of technology, not including the cost of hardware."

[ rhetoric ]

“Bioinformatics will be at the core of biology in the 21st century. In fields ranging from structural biology to genomics to biomedical imaging, ready access to data and analytical tools are fundamentally changing the way investigators in the life sciences conduct research and approach problems. Complex, computationally intensive biological problems are now being addressed and promise to significantly advance our understanding of biology and medicine. No biological discipline will be unaffected by these technological breakthroughs.”

BIOINFORMATICS IN THE 21st CENTURY

[ search ]

[ outbound ]

{bio,medical} informatics

[ rhetoric ]

[ search ]

[ outbound ]

[ schwag ]

[ et cetera ]